Therapy Areas: Diabetes
Daiichi Sankyo secures EMA validation for two triple-combination cholesterol therapies
29 October 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Thursday that it has received European Medicines Agency (EMA) validation for two marketing authorisation app...
Ascletis reports positive US Phase II topline results for ASC30 in diabetes
29 October 2026 - Chinese pharmaceutical company Ascletis Pharma Inc (HKEX:1672) on Wednesday reported positive topline results from its US Phase II study evaluating ASC30, an oral small molecule GLP-...
VibroSense Dynamics secures Thai regulatory approval for VibroSense Meter II
16 October 2026 - Swedish medical device company VibroSense Dynamics AB (Spotlight Stock Market: VSD B), which develops tools for diagnosing nerve damage in the hands and feet, said on Friday it has r...
Viking Therapeutics launches Phase 3 clinical programme for oral VK2735 in obesity
15 October 2026 - Clinical-stage biopharmaceutical company Viking Therapeutics Inc (NASDAQ:VKTX) announced on Wednesday the initiation of the SUNRISE Phase 3 clinical programme for oral VK2735, a dual...
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
8 October 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) said on Thursday that the US Food and Drug Administration (FDA) has accepted its supplemental New Drug ...
Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting
6 October 2026 - Mozart Therapeutics Inc, a developer of CD8 Treg network modulators for the treatment of autoimmune disease, announced on Monday the presentation of clinical and preclinical data for ...